印度 Emcure與賽諾菲簽署口服抗糖尿病產品分銷協議Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India

動脈網

2025/07/16

Emcure Pharmaceuticals埃姆庫爾製藥公司Ltd and有限公司和Sanofi India賽諾菲印度Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's有限公司在周三表示，他們已經就後者的產品簽訂了獨家分銷和推廣...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551527125"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551527125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551527125?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-16 20:56","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551527125","market":"us","top_or_hot":-1,"title":"印度 Emcure與賽諾菲簽署口服抗糖尿病產品分銷協議Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India","media":"動脈網","content":"<div>\n<p>Emcure Pharmaceuticals埃姆庫爾製藥公司Ltd and有限公司和Sanofi India賽諾菲印度Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's有限公司在周三表示，他們已經就後者的產品簽訂了獨家分銷和推廣...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162057159544e208&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>印度 Emcure與賽諾菲簽署口服抗糖尿病產品分銷協議Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n印度 Emcure與賽諾菲簽署口服抗糖尿病產品分銷協議Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-07-16 20:56</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Emcure Pharmaceuticals埃姆庫爾製藥公司Ltd and有限公司和Sanofi India賽諾菲印度Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's有限公司在周三表示，他們已經就後者的產品簽訂了獨家分銷和推廣...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162057159544e208&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162057159544e208&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162057159544e208&s=b","article_id":"2551527125","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162057159544e208&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551527125","pubTimestamp":1752670560,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Emcure Pharmaceuticals埃姆庫爾製藥公司Ltd and有限公司和Sanofi India賽諾菲印度Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's有限公司在周三表示，他們已經就後者的產品簽訂了獨家分銷和推廣協議。oral anti-diabetic products口服抗糖尿病產品in India with immediate effect.在印度立即生效。Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD  range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement.根據協議，Emcure將獨家分銷並推廣賽諾菲印度的OAD系列產品，包括Amaryl和Cetapin等品牌，兩家公司在聯合聲明中表示。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","GCVRZ":"Sanofi","SNYNF":"Sanofi","BK4007":"制药","BK4588":"碎股"},"translate_title":"India's Emcure and Sanofi sign distribution agreement for oral anti-diabetic products Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GCVRZ":1,"SNYNF":1,"SNY":0.9},"content_text":"Emcure Pharmaceuticals埃姆庫爾製藥公司Ltd and有限公司和Sanofi India賽諾菲印度Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's有限公司在周三表示，他們已經就後者的產品簽訂了獨家分銷和推廣協議。oral anti-diabetic products口服抗糖尿病產品in India with immediate effect.在印度立即生效。Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement.根據協議，Emcure將獨家分銷並推廣賽諾菲印度的OAD（口服抗糖尿病）系列產品，包括Amaryl和Cetapin等品牌，兩家公司在聯合聲明中表示。Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added.賽諾菲印度公司補充説，將繼續在印度和國際上的工廠擁有和生產這些品牌。'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' Emcure Pharmaceuticals CEO and MD Satish Mehta said.「憑藉我們在印度的強大分銷網絡，賽諾菲值得信賴的口服抗糖尿病藥物將提供更多給需要的患者，」埃姆庫爾製藥公司首席執行官兼董事總經理薩蒂什·梅赫塔表示。Further, he said, 'This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country.'此外，他表示：「這次合作補充了我們現有的糖尿病產品組合，為數百萬糖尿病患者提供了全面的服務，並支持在全國範圍內提供更好的糖尿病護理。」Live Events現場活動Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, 'With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them.'.同樣，賽諾菲東南亞和印度製藥總經理兼MCO負責人埃裏克·曼森表示：「憑藉Emcure在印度廣泛而深入的市場覆蓋，我們有信心充分挖掘我們一流的行業領先的口服降糖藥Amaryl和Cetapin的增長潛力。這一合作將真正使患者和信任並開具這些藥物的醫療專業人員雙方受益。」The two companies said there would be no people transition from兩家公司表示，不會有人員過渡從Sanofi India賽諾菲印度to Emcure under their distribution and promotion agreement.根據他們之間的分銷和推廣協議，轉讓給Emcure。(You can now subscribe to our（你現在可以訂閲我們的Economic Times WhatsApp channel經濟時報WhatsApp頻道))(You can now subscribe to our（你現在可以訂閲我們的Economic Times WhatsApp channel經濟時報 WhatsApp 頻道))","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}